B2M and melanoma: A clinical study reported that among 181 melanoma patients, 78 cases (43%) exhibited either complete or predominant (> 50%) loss of MHC‐I expression, which was linked to reduced transcription of HLA‐A, HLA‐B, HLA‐C and B2M, and closely linked to primary resistance to anti‐CTLA‐4 therapy.